Ectopic nonfunctioning pituitary adenoma in the sphenoid sinus.

B. Siegert,A. vz Mühlen,G. Brabant,W. Saeger,C. Vogt-Hohenlinde

DOI: https://doi.org/10.1210/JCEM.81.1.8550790

Abstract:Many clinicians are likely to share my confusion about statements made by Beldjord et al. (1) in their article (July 1995) on RET mutations in sporadic pheochromocytomas. It is certainly true that the identification of heritable mutations in the RET protooncogene as the cause of multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid cancer (MTC) has revolutionized the approach to presymptomatic screening of individuals at risk in such families. In contrast, the role of RET DNA testing in patients with apparently sporadic MTC or pheochromocytoma is still being evaluated. Beldjord et al. analyzed 28 sporadic unilateral pheochromocytomas and found RET mutations in the tumor tissue of 6 cases. None of the patients were shown to have germline (i.e. constitutional) RET mutation, which would have identified them, and family members, as being at risk for the spectrum of MEN-2-related tumors. The authors’ claim that their “findings have a profound clinical impact for the management of patients with supposedly sporadic pheochromocytomas” is therefore most curious. Clearly, their clinical recommendation that all patients with pheochromocytoma be tested to detect unsuspected germline RET mutations is not supported by their own data, given the failure to demonstrate that any of their 28 patients would have tested positively. Similar data were reported by Lindor et aI. (2) and Zedenius et al. (3). In none of their 29 patients and 10 patients, respectively, presenting with apparently sporadic pheochromocytoma was an unsuspected germline RET mutation detectable (yield of O/67 combining the three studies). Therefore, while more data need to be collected, Beldjord et aZ.‘s ringing endorsement of systematic RET genotyping in the particular low yield clinical situation of apparently nonfamilial, unilateral pheochromocytoma is quite difficult to support at this time. It should be noted that the yield of RET testing to detect unsuspected germline mutations in patients with sporadic MTC (3,4) may be considerably higher than in sporadic pheochromocytoma patients, and sporadic MTC is therefore much more likely to emerge as a clear indication for RET DNA testing.